z-logo
Premium
Risk of hepatitis B virus reactivation with direct‐acting antivirals against hepatitis C virus: A cohort study from Egypt and meta‐analysis of published data
Author(s) -
El Kassas Mohamed,
Shimakawa Yusuke,
AliEldin Zainab,
Funk AnnaLouise,
Wifi Mohamed Naguib,
Zaky Samy,
ElRaey Fathiya,
Esmat Gamal,
Fontanet Arnaud
Publication year - 2018
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.13874
Subject(s) - hbsag , medicine , hepatitis b virus , virology , hepatitis b , hepatology , hepatitis c virus , gastroenterology , immunology , virus
Background & Aims Hepatitis B virus ( HBV ) reactivation in chronic hepatitis C ( CHC ) patients treated with direct‐acting antivirals ( DAA s) became an issue. However, its frequency has been poorly estimated, because of the varying definitions used and evaluation of heterogeneous study populations, including those concurrently treated for HBV . Methods We prospectively followed HBV surface antigen ( HB sAg)‐positive Egyptians undergoing interferon‐free DAA s, to estimate the risk of HBV reactivation and HBV ‐related hepatitis. We also conducted a meta‐analysis to estimate the reactivation risk using published data obtained from a systematic review of PubMed/Embase, in addition to our Egyptian data. We applied a standard definition of HBV reactivation proposed by the international liver associations ( APASL and AASLD ). Results Of 4471 CHC patients, 35 HB sAg‐positive patients started interferon‐free DAA s without HBV nucleos(t)ide analogues in our Egyptian cohort. Ten experienced HBV reactivation (28.6%), of whom 1 developed hepatitis (10.0%). Our systematic review identified 18 papers. The pooled reactivation risk in HB sAg‐positive patients was 18.2% (95% CI : 7.9%‐30.7%) without HBV therapy and 0.0% (95% CI : 0.0%‐0.0%) with HBV nucleos(t)ide analogue. The pooled risk of hepatitis in those with HBV reactivation was 12.6% (95% CI : 0.0%‐34.7%). The pooled reactivation risk in HB sAg‐negative, antibody to HBV core antigen‐positive (anti‐ HB c‐positive) patients was negligible (0.1%, 95% CI : 0.0%‐0.3%), irrespective of the presence of antibody to HB sAg (anti‐ HB s). Conclusions We confirmed high HBV reactivation risk in HB sAg‐positive patients undergoing DAA s, with only a minority developing clinically important hepatitis. The risk is negligible for HB sAg‐negative anti‐ HB c‐positive patients.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here